Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Stock analysts at Leerink Partnrs increased their FY2023 EPS estimates for Alnylam Pharmaceuticals in a research report issued on Monday, January 8th. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.49) per share for the year, up from their prior […]
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally. Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.
FY2023 EPS Estimates for Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Raised by Analyst themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.